Skip to content

    Lupin Q1 FY27 earnings call

    LUPIN
    Healthcare·7 Aug 2026
    Management Summary

    Lupin reported a record Q1 FY27 with strong revenue and EBITDA growth, driven by diversified performance across all key geographies and significant margin expansion. While the US business saw robust sales, management anticipates moderation in the coming quarters due to increased competition in key products. The company remains focused on complex and innovative product pipelines and maintaining high compliance standards.

    Highlights

    9

    • Record quarter with total revenues from operations exceeding INR 8,000 crores and EBITDA exceeding INR 2,400 crores, respectively, for the first time in company history.

    • Achieved 16th consecutive quarter of YoY growth.

    • Ex-U.S. organic revenue growth was a strong 20%+ YoY, with double-digit growth in all key markets.

    • Gross Margins improved by 330 basis points YoY to 74.6% from 71.3% in Q1FY26.

    • EBITDA margins increased by 340 basis points YoY to 30% from 26.6% in Q1FY26.

    • India business grew 13.9% YoY, with core prescription business growing 15.1% (1.1x IPM growth).

    • Other Developed Markets grew 48% YoY, with European business growing 83% YoY.

    • Emerging Markets delivered an impressive 52% YoY growth, led by Brazil (117% YoY in local currency).

    • Received EIRs for Ankleshwar and Somerset with VAI status from U.S. FDA.

    Concerns

    3

    • Anticipated moderation in performance during the remainder of the year, especially in the U.S. from increased competitive intensity on two major products (Mirabegron and Tolvaptan).

    • Other Operating Income decreased 43% YoY to INR 60 crores (from INR 105 crores in Q1FY26) due to lower export benefits from PLI schemes.

    • EBITDA margins could see volatility due to new adjacency businesses (Diagnostics, Digital, OTC, CDMO) currently making losses, impacting margins by an estimated 1-1.5%.

    Key financials

    Single quarter

    09 metrics
    1. 01Revenue from Operations₹8,277 Cr+32%YoY
    2. 02EBITDA (ex-forex & other income)₹2,464 Cr+50%YoY
    3. 03EBITDA Margin30%
    4. 04Gross Margins74.6%
    5. 05R&D Spend₹608 Cr

    Segment breakdown

    US Business
    366 Mn Sales
    India Region
    ₹2,380 Cr Sales15.1% Core Prescription Business Growth6.1% Volume Growth67% Chronic Segment Share
    Other Developed Markets (Europe, Canada, Australia)
    ₹1,149 Cr Sales14% Share of Total Sales83% European Business Growth
    Emerging Markets
    ₹990 Cr Sales117% Brazil Growth (local currency)
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Debt

    Net ₹2,831 crores

    M&A

    VISUfarma

    acquisition · closed

    Guidance & targets

    18
    CategoryTargetPriority
    Revenue Growth
    Overall Revenue Growth
    high single-digit
    		High
    EBITDA Margins
    Overall EBITDA Margins
    around 25%
    		High
    US Business Sales
    US Business Sales
    USD 1.1 billion to USD 1.2 billion
    		High
    US Business Growth
    US Business Growth Trajectory
    back to growth trajectory
    		High
    US Product Launches
    Number of US Product Launches
    50 plus products
    		High
    US Product Filings
    Number of US Product Filings
    more than 15 products
    		High
    India Formulations Business Growth
    India Formulations Business Growth vs IPM
    1.2x to 1.3x
    		High
    India Chronic Segment Share
    Chronic Segment Share in India Portfolio
    70%
    		High
    India Novel Proprietary Products
    Contribution of Novel Proprietary Products to India Revenues
    one third
    		High
    Europe Business Growth
    Europe Business Growth
    10%-20%
    		High
    R&D Spend
    R&D as % of Sales
    around 8%
    		High
    Effective Tax Rate (ETR)
    Effective Tax Rate
    27% - 28%
    		High
    Biosimilars Business
    Biosimilars Business Scale (US/Europe)
    couple of hundred million dollars
    		High
    Apixaban 505(b)(2) Launch
    Apixaban 505(b)(2) Commercial Launch
    January '27
    		High
    Fluticasone Nasal Spray Approval
    Fluticasone Nasal Spray Rx Approval
    this year
    		High
    Fluticasone Nasal Spray Approval
    Fluticasone Nasal Spray OTC Approval
    FY28
    		High
    Spiriva Respimat Filing
    Spiriva Respimat Filing
    this fiscal year
    		High
    Ellipta Franchise ANDA Filing
    Ellipta Franchise ANDA Filing
    later this fiscal year
    		High

    What to watch in Q2 FY27

    5

    US Sales Performance

    next quarter (Q2 FY27)
    CurrentUSD 366 million in Q1 FY27
    TargetStabilization within USD 250-280 million/quarter range

    Why it matters

    To assess the impact of new competition in Tolvaptan and Mirabegron on US revenue.

    We expect revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters.

    Risks & concerns

    4
    RiskSeverity

    Increased Competition in US Generics

    Increased competition in Mirabegron and Tolvaptan will lead to moderation in US performance from Q2 FY27 onwards. — Management acknowledged

    high

    Geopolitical Environment Impact on Costs

    Uncertain geopolitical environment could lead to price increases and impact gross margins. — Management acknowledged

    medium

    Losses from Adjacency Businesses

    New businesses (Diagnostics, Digital, OTC, CDMO) are currently loss-making, impacting EBITDA margins by 1-1.5%. — Management acknowledged

    medium

    Lower PLI Scheme Benefits

    Other Operating Income decreased 43% YoY due to lower export benefits from PLI schemes. — Management acknowledged

    low

    Q&A highlights

    8

    “In Q1, you don't have any additional competition on Tolvaptan. And from Q2 onwards, you will start seeing the impact of Apotex and Teva. We also expect in September, we could potentially have one more entrant. We expect to be a four-player market with Tolvaptan. And we expect the market to grow as well for the molecule, given that it is still 40% generic conversion so far. But given the additional competition, we expect pricing to come down, and obviously also some share re-distribution. So, we expect Tolvaptan to come down over the next couple of quarters. Mirabegron has already seen pressure in the first quarter, and we expect that to be a full quarter impact from Q2 onwards. We expect revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters.”

    Clarifies the reasons for the anticipated decline in US sales from Q1 levels, attributing it to new competition in key products like Tolvaptan and Mirabegron.

    asked by Shyam Srinivasan

    2 min read6 chapters

    Detailed Narrative

    01

    Record Q1 FY27 Performance and Diversified Growth

    Lupin achieved a record Q1 FY27 with total revenues exceeding INR 8,000 crores and EBITDA exceeding INR 2,400 crores, marking its 16th consecutive quarter of YoY growth. The company reported a strong ex-U.S. organic revenue growth of 20%+ YoY, with double-digit growth across all key markets including India, Other Developed Markets, and Emerging Markets. Gross margins significantly improved by 330 bps to 74.6%, and EBITDA margins expanded by 340 bps to 30%.

    02

    US Business Outlook and Pipeline Strategy

    The US business recorded robust sales of USD 366 million, a 30% YoY increase in constant currency. However, the full-year guidance is set at USD 1.1-1.2 billion, anticipating moderation from Q2 FY27 due to increased competition in key products like Mirabegron and Tolvaptan. Lupin plans to launch over 50 products in the next three years, including 10 exclusive first-to-files and 5 biosimilars, aiming for a return to growth trajectory from FY28 onwards by doubling the share of complex products.

    03

    India Business Momentum and Innovation Focus

    India's business grew 13.9% YoY, with the core prescription segment outperforming IPM at 15.1% growth. The chronic segment now constitutes 67% of the portfolio, targeted to reach 70% in the next five years. The company aims for novel proprietary products to contribute one-third of India revenues within a decade, leveraging in-house development, in-licensing, and innovative New Chemical Entities (NCEs) like Bofanglutide.

    04

    Strong Performance in Other Developed and Emerging Markets

    Other Developed Markets (Europe, Canada, Australia) saw a 48% YoY growth, contributing 14% to total sales, with European business alone growing 83% YoY. Emerging Markets delivered an impressive 52% YoY growth, significantly driven by Brazil's 117% YoY growth in local currency. The company is establishing a presence in the diabetes metabolic space in these markets with products like Dapagliflozin and Empagliflozin.

    05

    R&D and Compliance Updates

    R&D spend for the quarter was 7.4% of sales (INR 608 crores), with a full-year expectation of around 8%. Focus remains on complex and specialty platforms, including respiratory, injectables, and biosimilars. In compliance, Lupin received EIRs with VAI status for Ankleshwar and Somerset facilities and is on track with remediation efforts for Pithampur Unit II, underscoring its commitment to quality standards.

    06

    EBITDA Margin Outlook and Adjacency Impact

    Despite strong Q1 EBITDA margins of 30%, the full-year guidance is around 25%, reflecting anticipated moderation. This is attributed to increased competition in the US, potential impacts from geopolitical-driven cost increases, and the current loss-making status of new adjacency businesses (Diagnostics, Digital, OTC, CDMO). These adjacencies are currently impacting EBITDA margins by 1-1.5% but are expected to break even and contribute positively in future quarters.

    This is an AI-generated summary of a publicly available earnings call transcript.